Is PT-141 (Bremelanotide) Legal in Colorado? How to Access It With a Prescription
HealthRX.com
Vyleesi is prescription-only; compounded PT-141 is not the same
Key numbers
- 1.75 mgVyleesi dose injected under the skin as needed for premenopausal women with acquired, generalized HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesMinimum time before anticipated sexual activity to inject Vyleesi, per the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 8 weeksTreatment with Vyleesi should be stopped after 8 weeks if symptoms have not improvedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Share of Vyleesi patients reporting nausea in trials; placebo group was 1.3%Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Federal status / Prescription drug, approved as Vyleesi June 21, 2019 (NDA 210557) [1][2]
- Approved use / Acquired, generalized HSDD in premenopausal women [1]
- Approved form / 1.75 mg subcutaneous autoinjector, used as needed [1]
- Boxed warning / None; no REMS in the label or the 2019 approval letter [1][2]
- Compounded or research-use PT-141 / Not Vyleesi, not FDA-approved [3][1]
- Label cautions / Blood pressure rise, nausea, focal hyperpigmentation [1]
Is PT-141 legal in Colorado?
Bremelanotide's legal standing in the US comes from its FDA approval. Vyleesi is a prescription drug for premenopausal women with acquired, generalized HSDD, meaning low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. FDA approved it on June 21, 2019 under NDA 210557; the current holder is Cosette Pharmaceuticals [1][2].
The label limits use: it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1]. Colorado's own prescribing and pharmacy statutes are not summarized on this page.
Does PT-141 need a prescription?
Yes. Vyleesi is a prescription-only, self-injected product [1]. The label directs 1.75 mg under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. It says more than eight doses per month is not recommended, and that treatment should be stopped after 8 weeks if symptoms have not improved [1]. There is no boxed warning, and no REMS appears in the label or the 2019 approval letter [1][2].
What people on Reddit report
Replies from people asking how to get a prescription for this peptide and advising a doctor visit before use. Accounts describe obtaining it through a clinic or going to a doctor first.
I got a prescription from a local wellness clinicRead the source discussion
I wouldn't do an end run if you're going to use this. Definitely see a doctor first.Read the source discussion
Questions worth asking
Compounded and research-use PT-141
PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1]. Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026), is not in any category on FDA's bulk-substance lists, and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][5][6]. Being absent from those lists does not make a compounded bremelanotide product an approved drug.
What the label says to watch for
Each dose transiently raises blood pressure and lowers heart rate [1]. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after dosing, with heart rate down up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed once daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease [1].
Nausea was reported by 40.0% of Vyleesi patients versus 1.3% on placebo; 13% needed anti-nausea medicine and 8% stopped the trials because of it [1]. Pre-treating with oral ondansetron did not reduce nausea in a phase 4 study of 228 healthy women and is not recommended [1]. Focal hyperpigmentation, including the face, gums and breasts, was reported by 1% of patients versus none on placebo, with higher risk in darker skin and with daily dosing [1].
The label says to avoid oral naltrexone products intended for alcohol or opioid addiction because Vyleesi may significantly decrease naltrexone exposure, and to use effective contraception and stop Vyleesi if pregnancy is suspected [1]. FDA approved a labeling supplement on October 22, 2026 that updates the pregnancy section and the patient information; that text was not yet in DailyMed on October 28, 2026 [8].
Is PT-141 approved for men?
No. The label excludes men and postmenopausal women [1]. A phase 1/2 study of subcutaneous PT-141 reported a statistically significant erectile response at 4 and 6 mg in men with erectile dysfunction who had an inadequate response to sildenafil [7]. That is not an approved use.
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is PT-141 legal in Colorado?
Do I need a prescription for PT-141?
Is compounded PT-141 the same as Vyleesi?
Is PT-141 approved for men or postmenopausal women?
What is the approved dosing?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Can you get PT-141 over the counter?
No. Vyleesi is not sold over the counter. It is a prescription-only, self-injected product, and PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug.
How do I get PT-141 peptide?
Vyleesi requires a prescription. Its label directs 1.75 mg under the skin as needed, at least 45 minutes before anticipated sexual activity. Compounded and research-use PT-141 is not Vyleesi, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing. Colorado-specific prescribing and pharmacy rules are not summarized here.
References
Show all 9 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-42.
- U.S. Food and Drug Administration. Vyleesi (NDA 210557) labeling supplement S-005 approval letter, 2026.
- Reddit participants. PT-141 Experience - it absolutely works (r/erectiledysfunction). Accessed 2026-11-11.